iBET and Hovione Launch New Joint Venture: ViSync Technologies
Addressing Unmet Technical Needs in Cell and Gene Therapy
On September 18th, iBET and Hovione officially launched ViSync® Technologies, a new joint venture in cell and gene therapy solutions.
From left to right: Manuel Carrondo (iBET – Vice President), Jean-Luc Herbeaux (Hovione – CEO), Paulo Granadeiro (Hovione – Director Transformational Projects), Teresa Alves (Hovione – Senior Director, Strategic Alliances), Paula Alves (iBET – CEO) and Pedro Cruz (iBET – CTOO).
ViSync® aims to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy sector. The venture will leverage Hovione’s extensive expertise in pharmaceutical development, particle engineering and industrialization, with iBET’s cutting-edge research in biotechnological sciences.
One of the first focus areas of ViSync® will be to develop technologies that improve delivery and stabilization of new modality therapies.
The launch ceremony was attended by representatives from both iBET and Hovione, who played an important role in the establishment of the company.
The event took place at the iBET Biofarma Building in Oeiras, where ViSync will also be headquartered.
From left to right: João Almeida Lopes (iBET – President), Paula Alves (iBET – CEO) and Jean-Luc Herbeaux (Hovione – CEO)